INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Maitland, MD
University of Chicago
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Chicago
Chicago, Illinois, United States
- Billings Clinic
Billings, Montana, United States
- New York Oncology Hematology, P.C.
Albany, New York, United States
- Dayton Oncology and Hematology
Kettering, Ohio, United States
- Signal Point Hematology/oncology, Inc.
Middletown, Ohio, United States
- Cancer Centers of the Carolinas
Greenville, South Carolina, United States
- Mary Crowley Medical Research Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2008
- Primary completion
- —
- Completion
- 30 Nov 2008
- Last update posted
- 9 Feb 2012
- Registered enrollment
- 0
- Registry id
- NCT00472771
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.